Nate Hill, co-founder & CEO, Strive Pharmacy, breaks down looming questions around the completed FDA PCAC hearing on peptides.
Nate Hill
Advertisement
Nate Hill is CEO and Co-Founder of Strive Pharmacy and a national advocate for personalized medicine. With nearly a decade of experience in healthcare, he works to expand access to compounded medications while challenging outdated pharmacy models that limit patient choice.
Hill has represented Strive in Washington, D.C., speaking on access, affordability and the importance of regulatory standards within compounding.
Articles by Nate Hill
Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category one announcement for peptides.
Nate Hill, co-founder & CEO, Strive, explains how Strive is managing peptide uncertainty by pre-sourcing API, running stability and testing, and working with legal counsel to calibrate risk.
Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack.
Nate Hill, co-founder & CEO of Strive Pharmacy, warns that restricting peptides without establishing a clear regulated pathway would push demand deeper into the gray market.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5